Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.

[1]  S. Vishnubhatla,et al.  Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy , 2021, Pediatric blood & cancer.

[2]  L. Constine,et al.  Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group , 2018, Cancer.

[3]  Michael Hauptmann,et al.  Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. , 2017, Blood.

[4]  J. Raemaekers,et al.  Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Radford,et al.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[6]  Allen R. Chen,et al.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  U. Bick,et al.  Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up. , 2014, Deutsches Arzteblatt international.

[9]  H. Eich,et al.  Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Pötter,et al.  Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Kelly,et al.  Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[13]  W. Klapper,et al.  Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. S. Turner,et al.  A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. , 2009, Blood.

[15]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Lamborn,et al.  VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[18]  R. Pötter,et al.  High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Behm,et al.  Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[21]  V. Gerein,et al.  [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82]. , 1986, Klinische Padiatrie.

[22]  A. Miller,et al.  Simple rule for calculating normal erythrocyte sedimentation rate. , 1983, British medical journal.

[23]  L. Constine,et al.  Pediatric Hodgkin Lymphoma , 2020, Hodgkin Lymphoma.

[24]  Wi Wei,et al.  Prognostic factors , 1998, British Journal of Cancer.